BridgeBio Pharma, Inc. Common Stock (BBIO) is a publicly traded Healthcare sector company. As of August 7, 2026, BBIO trades at $82.36 with a market cap of $16.07B and a P/E ratio of -22.08. BBIO moved +0.45% today. Year to date, BBIO is +7.19%; over the trailing twelve months it is +66.61%. Its 52-week range spans $25.34 to $93.42. Analyst consensus is strong buy with an average price target of $107.39. Rallies surfaces BBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
19 analysts cover BBIO: 0 strong buy, 18 buy, 1 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $107.39.
| Metric | Value |
|---|---|
| Price | $82.36 |
| Market Cap | $16.07B |
| P/E Ratio | -22.08 |
| EPS | $-3.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.42 |
| 52-Week Low | $25.34 |
| Volume | 730.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $579.96M |
| Net Income | $-729.88M |
| Gross Margin | 95.13% |
19 analysts cover BBIO: 0 strong buy, 18 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $107.39.